Health Care

California's Department of Motor Vehicles will miss a year-end deadline to adopt rules governing the self-driving cars of the future.

A trade deal between the U.S. and China could end tariffs on $1 trillion in global sales of semiconductors, MRI machines, GPS devices, printer ink cartridges, video game consoles and other high-tech items.

The on-demand ride-sharing app Lyft says it is starting limited service in New York City after reaching agreement with state and city officials to resolve regulatory issues.

AbbVie's $55B deal to buy Irish drug maker Shire would mark the largest tax inversion ever, as a growing number of U.S. firms eye lower rates overseas.

When many of us have a medical appointment we're concerned about our finances: how much will we owe out-of-pocket? What's our co-pay? But next time, you may also want to ask your doctors about their financial situation.

Moody's Investors Service says forecast premium hikes for 2015 under the Affordable Care Act are a positive for insurance carriers. 

As more people enroll in Medicaid programs nationwide, some states are experiencing budgetary pressures. Does this mean taxpayers wind up paying the costs for this new pool of enrollees?

Pfizer said it will submit a new application with U.S. regulators for its investigational breast cancer drug, palbociclib.

A new report from Goldman Sachs shows how the Affordable Care Act may eliminate some worries from wanna-be retirees.

Under the Affordable Care Act, businesses with a certain amount of full-time workers have to offer coverage or face penalties. But could narrowing coverage options veer unhealthy workers on state and federal exchanges?

Massachusetts is the latest state to scrap or overhauled its health exchange in the wake of the Affordable Care Act’s first enrollment period.

The drugmakers plan to fight a federal verdict ordering them to pay $9 billion after a jury ruled they failed to disclose Actos cancer risks.

MannKind said the FDA extended the review date of its inhaled insulin treatment by three months so that it has more time to review the data submitted by the drug company and the FDA's third-party committee. 

Shares of Halozyme slumped more than 23% Friday after the company halted a trial for its experimental pancreatic drug amid concerns from a third-party review committee. 

Shares of MannKind skyrocketed 80% after health regulators recommended almost unanimously that its diabetes drug Afrezza be granted approval.

Shares of Intuitive Surgical jumped 14% after the device maker said its next-generation non-invasive surgical system was approved for marketing in the U.S. 

Eli Lilly forecast a decline in earnings, in line with views, hurt by cheaper generic forms of its Zyprexa and Cymbalta drugs.

Attention consumers who need health coverage by Jan.1, just  singing up for coverage on a state or federal exchange doesn’t mean you have coverage.

The insurer expects a delay in the enrollment period for the state-based health exchanges after the rocky start to this marketplace.

AstraZeneca appointed former GlaxoSmithKline executive Marc Dunoyer as chief financial officer on Thursday and revealed an 18% decline in third-quarter profit.